2022
Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants
Bikdeli B, Tajrishi F, Sadeghipour P, Talasaz AH, Fanikos J, Lippi G, Siegal DM, Eikelboom JW, Monreal M, Jimenez D, Connors JM, Ageno W, Barnes GD, Piazza G, Angiolillo DJ, Parikh SA, Kirtane AJ, Lopes RD, Bhatt DL, Weitz JI, Mehran R, Krumholz HM, Goldhaber SZ, Lip GYH. Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. JAMA Cardiology 2022, 7: 747-759. PMID: 35648414, DOI: 10.1001/jamacardio.2022.1292.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsRandomized clinical trialsAcute VTE treatmentDose adjustmentOral anticoagulantsLow-intensity treatmentPrimary preventionLarge registriesVTE treatmentHigh-risk medical patientsStable atherosclerotic vascular diseaseHigh-risk cancer patientsLarge randomized clinical trialsSecondary VTE preventionPeripheral artery diseaseAtherosclerotic vascular diseaseDaily clinical practiceRoutine practice patternEvidence of safetyRecent revascularizationStroke preventionVTE preventionArtery diseaseMedical patientsCancer patients
2010
Optimizing statin treatment for primary prevention of coronary artery disease.
Hayward RA, Krumholz HM, Zulman DM, Timbie JW, Vijan S. Optimizing statin treatment for primary prevention of coronary artery disease. Annals Of Internal Medicine 2010, 152: 69-77. PMID: 20083825, DOI: 10.7326/0003-4819-152-2-201001190-00004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCholesterol, LDLClinical Trials as TopicComputer SimulationCoronary Artery DiseaseDrug Administration ScheduleFemaleGuideline AdherenceHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedPrimary PreventionQuality-Adjusted Life YearsRisk FactorsSensitivity and SpecificityTreatment OutcomeConceptsHigh-dose statinsQuality Enhancement Research InitiativeStatin therapyMore QALYsNational Cholesterol Education Program III guidelinesTreatment approachesCoronary artery disease preventionVeterans Affairs Health Services ResearchDoses of statinsCoronary artery diseaseRisk factor dataAvailable clinical dataYears of treatmentTarget approachBase-case analysisHealth services researchPersons 75 yearsStatin doseStatin trialsCAD eventsStatin treatmentArtery diseaseCAD riskPrimary preventionMyocardial infarction
2003
Are Statins Indicated for the Primary Prevention of CAD in Octogenarians? Angagonist Viewpoint
Foody JM, Krumholz HM. Are Statins Indicated for the Primary Prevention of CAD in Octogenarians? Angagonist Viewpoint. The American Journal Of Geriatric Cardiology 2003, 12: 357-360. PMID: 14610384, DOI: 10.1111/j.1076-7460.2003.02912.x.Peer-Reviewed Original ResearchConceptsCoronary artery diseasePrimary preventionArtery diseaseOvert coronary artery diseaseRisk of myositisCardiovascular disease eventsRole of statinsUse of statinsAge 65 yearsBalance of risksCardiovascular eventsStatin therapyPatient preferencesCholesterol levelsCardiovascular diseaseOctogenariansClinical uncertaintyDisease eventsCurrent evidenceStatinsAge groupsDiseasePreventionRiskMyositis
1997
Guide to primary prevention of cardiovascular diseases. A statement for healthcare professionals from the Task Force on Risk Reduction. American Heart Association Science Advisory and Coordinating Committee.
Grundy S, Balady G, Criqui M, Fletcher G, Greenland P, Hiratzka L, Houston-Miller N, Kris-Etherton P, Krumholz H, LaRosa J, Ockene I, Pearson T, Reed J, Washington R, Smith S. Guide to primary prevention of cardiovascular diseases. A statement for healthcare professionals from the Task Force on Risk Reduction. American Heart Association Science Advisory and Coordinating Committee. Circulation 1997, 95: 2329-31. PMID: 9142014, DOI: 10.1161/01.cir.95.9.2329.Peer-Reviewed Original Research